Karuna Therapeutics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Karuna Therapeutics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 7 currently recruiting 3 completed later-stage tilt top decile by trial count

Karuna Therapeutics: 11 sponsored US clinical trials, 7 recruiting.

Karuna Therapeutics sponsors 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 3 completed. 7 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 4 trials.

Top-decile sponsor footprint

Karuna Therapeutics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 4

KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

NCT07257120
RECRUITING Phase 1

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

NCT07204418
RECRUITING Phase 1

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
RECRUITING Phase 3

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787
RECRUITING Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949
RECRUITING Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
RECRUITING Phase 3

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05304767
ACTIVE NOT RECRUITING Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224
COMPLETED Phase 1

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

NCT06729970
COMPLETED Phase 3

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCT04820309
COMPLETED Phase 2

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

NCT03697252

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 3 6
Phase 4 1

Therapeutic Areas

Healthy Volunteers 4
Psychosis Associated With Alzheimer's Disease 3
Schizophrenia 3
Alzheimer Disease 1

Where Karuna Therapeutics enrollment is open (later-stage tilt)

7 recruiting of 11 indexed (64% open); 3 completed (27%).

Phase mix: 7 late (III/IV) vs 4 early (I/II) (later-stage heavy).

Top condition: Healthy Volunteers (4 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Karuna Therapeutics: open-pipeline peers nationwide

Peers matched on 11 registered trials and 64% open enrollment, not the therapeutic-area sidebar.

Karuna Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Karuna TherapeuticsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeCanadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care SystemNurix Therapeutics
Karuna Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Karuna Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 64% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Karuna Therapeutics page

11 registered trials is a research-attention snapshot, not an endorsement of Karuna Therapeutics or any single study.

  • 7 of Karuna Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy Volunteers is the condition Karuna Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Karuna Therapeutics pipeline card: 11 registered trials from official public datasets.Report a data error.